Xilio Therapeutics (XLO) Current Leases (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Current Leases data on file, last reported at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 12.89% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (up 12.89% YoY), and the FY2025 full-year result was $1.3 million, up 13.05% from the prior year.
• Current Leases improved to $1.4 million in Q1 2026, from $1.3 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.4 million in Q1 2026 to a low of $829000.0 in Q1 2022.
• A 5-year average of $1.1 million and a median of $1.1 million in 2024 frame the typical range for Current Leases.
• Across the five-year window, Current Leases climbed 14.88% in 2022 and gained 12.89% in 2026, its largest moves.
• Tracing XLO's Current Leases over 5 years: stood at $918000.0 in 2022, then climbed by 14.05% to $1.0 million in 2023, then grew by 13.47% to $1.2 million in 2024, then gained by 13.05% to $1.3 million in 2025, then climbed by 3.05% to $1.4 million in 2026.
• Business Quant data shows XLO's Current Leases at $1.4 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.